Prophylactic platelet transfusions in patients with haematological malignancies – lessons from the TOPPS trial
People with haematological malignancies are the largest patient group who use platelet components, and platelet transfusions are an important supportive therapy during treatment with chemotherapy or haematopoietic stem cell transplantation (HSCT).
| Κύριος συγγραφέας: | |
|---|---|
| Μορφή: | Conference item |
| Έκδοση: |
Wiley
2016
|